IQVIA Holdings Inc
NYSE:IQV

Watchlist Manager
IQVIA Holdings Inc Logo
IQVIA Holdings Inc
NYSE:IQV
Watchlist
Price: 201.23 USD -1.37% Market Closed
Market Cap: 36.5B USD
Have any thoughts about
IQVIA Holdings Inc?
Write Note

IQVIA Holdings Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IQVIA Holdings Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
IQVIA Holdings Inc
NYSE:IQV
Net Income (Common)
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
42%
CAGR 10-Years
15%
Thermo Fisher Scientific Inc
NYSE:TMO
Net Income (Common)
$6.1B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Net Income (Common)
$3.9B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
4%
West Pharmaceutical Services Inc
NYSE:WST
Net Income (Common)
$499.6m
CAGR 3-Years
-7%
CAGR 5-Years
17%
CAGR 10-Years
15%
Mettler-Toledo International Inc
NYSE:MTD
Net Income (Common)
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Net Income (Common)
$1.4B
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
7%
No Stocks Found

IQVIA Holdings Inc
Glance View

Market Cap
36.5B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

IQVIA Holdings Inc. stands at the crossroads of healthcare and technology, blending innovative data analytics with deep industry expertise to enhance the clinical development and commercialization of pharmaceuticals. Founded in 2016 from the merger of IMS Health and Quintiles, IQVIA has rapidly positioned itself as a leader within the life sciences sector. The company's core mission revolves around leveraging vast sources of healthcare data and advanced artificial intelligence to provide actionable insights, streamline drug development processes, and facilitate improved patient outcomes. With a global footprint extending across more than 100 countries, IQVIA serves a diverse clientele, including biopharmaceutical companies, healthcare providers, and government organizations, making it a pivotal player in the ever-evolving healthcare landscape. For investors, IQVIA represents a compelling opportunity that combines robust financial performance with strong market demand driven by the growing complexities of drug development and regulatory environments. As the healthcare sector increasingly turns to data-driven decision-making, IQVIA's extensive suite of services—including real-world evidence, market access solutions, and technology-enabled clinical trial services—positions it favorably in a market ripe for innovation. The company's commitment to research and development, coupled with strategic partnerships and acquisitions, fuels its long-term growth trajectory. Furthermore, IQVIA's resilience in navigating industry shifts, highlighted by its consistent revenue growth and healthy profit margins, reflects a business model that is not only scalable but also agile enough to adapt to the challenges and opportunities of modern medicine.

IQV Intrinsic Value
260.09 USD
Undervaluation 23%
Intrinsic Value
Price

See Also

What is IQVIA Holdings Inc's Net Income (Common)?
Net Income (Common)
1.4B USD

Based on the financial report for Sep 30, 2024, IQVIA Holdings Inc's Net Income (Common) amounts to 1.4B USD.

What is IQVIA Holdings Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
15%

Over the last year, the Net Income (Common) growth was 26%. The average annual Net Income (Common) growth rates for IQVIA Holdings Inc have been 22% over the past three years , 42% over the past five years , and 15% over the past ten years .

Back to Top